Tetrabenazine (Ro 1-9569; trade name: Nitoman and Xenazin), a VMAT-inhibitor, is an FDA approved drug for the treatment of symptomatic treatment of hyperkinetic movement disorder.

(+)-Tetrabenazine ((+)-TBZ; (3R,11bR)-TBZ; (3R,11bR)-Tetrabenazine) is a potent and reversible inhibitor of vesicular monoamine transporter 2 (VMAT-2) which inhibits transport by VMAT2 with 10-fold greater potency than transport by VMAT1.

Deutetrabenazine (formerly known as SD-809; GTPL8707; tetrabenazine-d6; trade name Austedo), the hexa-deuterated form of tetrabenazine, is an orally bioactive, small-molecule vesicular monoamine transporter 2 (VMAT2) inhibitor which has been approved by FDA in 2017 for the treatment of chorea associated with Huntington’s disease and tardive dyskinesia.

Valbenazine (formerly NBI98854; MT5199; NBI-98854; MT-5199; trade name: Ingrezza) is a potent and selective inhibitor of VMAT2 (vesicular monoamine transporter 2) with potential usefulness in the treatment of TD/tardive dyskinesia (uncontrollable movement of the face, tongue, or other body parts).

Tetrabenazine (Racemate) is a selective and reversible inhibitor of vesicular monoamine transporter-2 (VMAT-2).

Radafaxine HCl (also known as GW-353162A) is a novel and potent DAT (dopamine transporter) and NET(norepinephrine transporter) transporters inhibitor, it is also an nAChR family modulator.